Large-scale hepatitis C combating campaigns in Egypt and Georgia; past, current and future challenges

  • Fatma Abdelaziz Amer Zagazig University, Zagazig, Egypt
Keywords: Hepatitis C virus, Egypt, Georgia, direct acting antivirals


Hepatitis C virus (HCV) infection is a major worldwide problem which should be adequately combated. This review summarizes two successful model programs to eradicate Hepatitis C in two countries; Egypt and Georgia. Egypt tops the list of nations affected by HCV, and Georgia is ranked among other countries with huge HCV burden. Currently, both countries are on their ambitious way to making history and completely eliminate Hepatitis C virus infections.

The first comprehensive approach to reduce the burden of hepatitis C and associated diseases in Egypt was achievable with the formulation of the National Committee for Control of Viral Hepatitis (NCCVH) in 2006. Assisted by international and national stalk holders, Georgia started its nation- wide HCV fighting program in 2015. Elements of programs mostly addressed in both countries included simplifying and improving access to the package of diagnosis and care- providing effective, affordable or free of charge treatment- issuing, applying and regularly updating practice guidelines- improving surveillance, monitoring, and research focusing specifically on the risky groups- emphasizing infection control (IC) - encouraging patient and community engagement and increasing public and political commitment. Interventions are still going on to eradicate HCV infection in Egypt by 2030 and in Georgia by 2020. Lessons gained from this program can educate comparable activities in different nations and help control the worldwide epidemic of viral hepatitis.

Author Biography

Fatma Abdelaziz Amer, Zagazig University, Zagazig, Egypt

Department of Medical Microbiology and Immunology,

Professor of Microbiology and Immunology

How to Cite
Amer FA (2018) Large-scale hepatitis C combating campaigns in Egypt and Georgia; past, current and future challenges. J Infect Dev Ctries 12:404-414. doi: 10.3855/jidc.9784